PMID: 9442415Jan 27, 1998Paper

Transurethral alprostadil with MUSE (medicated urethral system for erection) vs intracavernous alprostadil--a comparative study in 103 patients with erectile dysfunction

International Journal of Impotence Research
H Porst

Abstract

A comparative study in 103 unselected patients with erectile dysfunction between MUSE up to 1000 micrograms and intracavernous Alprostadil (Prostavasin) up to 20 micrograms provided total response-rates of 43% (MUSE) vs 70% (Prostavasin). Complete rigid erections were reached in 10% (MUSE) vs 48% (Prostavasin). The average end-diastolic flow values in the deep penile arteries ranged between 9.2-9.4 cm/s after MUSE and 4.5-4.8 cm/s after i.c. Alprostadil confirming the investigator's assessment, that in the vast majority of patients MUSE were not able to induce a complete cavernous smooth muscle relaxation. In terms of side effects the reported penile pain/ burning-rate after MUSE was 31.4% compared to 10.6% after i.c. Alprostadil. In addition after MUSE clinically relevant systemic side-effects like dizziness, sweating and hypotension occurred in 5.8% with syncope in 1%. No circulatory side-effects were encountered after i.c. Alprostadil. Urethral bleeding after MUSE-application was observed in 4.8%. Due to the superior efficacy and lower side-effects self-injection therapy with Alprostadil remains the 'Gold Standard' in the management of male impotence. MUSE should be reserved for a subset of patients suffering from erectile d...Continue Reading

Citations

Jun 27, 2002·Current Urology Reports·C C Carson
Jun 27, 2002·Current Urology Reports·C D ZippeA Agarwal
Nov 12, 2002·Current Urology Reports·Ajay Nehra, Haluk Kulaksizoglu
Nov 5, 2013·Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie·G KarsentyF Bruyère
Feb 13, 1999·Disease-a-month : DM·M E Wierman
Dec 21, 2000·Trends in Pharmacological Sciences·T J BivalacquaP J Kadowitz
Jul 1, 2005·International Journal of Impotence Research·C ZippeR Raina
Jan 5, 2006·International Journal of Impotence Research·E R SchwarzS Rosanio
Mar 16, 2000·Clinical Endocrinology·A LevyC Gingell
Oct 2, 2001·BJU International·D G Hatzichristou, E S Pescatori
Aug 15, 2002·BJU International·J Shah
Jun 15, 2000·The New England Journal of Medicine·T F Lue
Dec 1, 1996·Epilepsia·G T Guldner, M J Morrell
Aug 19, 2000·BMJ : British Medical Journal·D Ralph, T McNicholas
Jul 18, 2002·Japanese Journal of Pharmacology·John A Thomas
Nov 23, 2012·Drugs·Pierre Costa, Axel-Juerg Potempa
Jul 11, 2003·The Journal of Urology·Raymond A Costabile
Dec 27, 2013·Expert Opinion on Pharmacotherapy·Vishwanath Hanchanale, Ian Eardley
Oct 30, 1998·Hospital Practice·M E Wierman, C K Cassel
May 2, 2001·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·D Vitezic
Jan 23, 2010·The Journal of Sexual Medicine·Ian EardleySung Won Lee
Jan 25, 2013·The Journal of Sexual Medicine·Hartmut PorstUNKNOWN ISSM Standards Committee for Sexual Medicine
Nov 24, 1999·Lancet·A Morgentaler
May 20, 2015·Der Urologe. Ausg. A·M TrottmannC G Stief
Jun 1, 2007·American Journal of Men's Health·Rupesh RainaCraig D Zippe
Jul 16, 1999·Mayo Clinic Proceedings·A NehraR B Moreland
Jul 31, 2002·Heart Disease·Arnold Melman, George J Christ
Feb 14, 2006·Nature Clinical Practice. Urology·Duncan J SummertonDavid J Ralph
Feb 13, 2004·International Journal of Impotence Research·T BschleipferC Sparwasser
Dec 31, 2015·Current Opinion in Urology·Kyriakos MoisidisKonstantinos Hatzimouratidis
Aug 23, 2019·Expert Opinion on Drug Safety·Murat Gul, Ege Can Serefoglu
Oct 14, 2006·Current Opinion in Urology·C G McMahon
May 29, 1999·British Journal of Nursing : BJN·D Rutherford, F J Duffy
Dec 26, 2018·Expert Opinion on Drug Metabolism & Toxicology·Tan V LeWayne J G Hellstrom
Feb 27, 2003·BJU International·F MontorsiC Stief
Jan 10, 2001·The Medical Journal of Australia·C G McMahon
Nov 19, 2020·International Journal of Impotence Research·Thiago Fernandes Negris LimaRanjith Ramasamy

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.